Literature DB >> 11027491

Amyloid beta protein starting pyroglutamate at position 3 is a major component of the amyloid deposits in the Alzheimer's disease brain.

Y Harigaya1, T C Saido, C B Eckman, C M Prada, M Shoji, S G Younkin.   

Abstract

The amyloid beta protein (Abeta) deposited in the Alzheimer's disease (AD) brain is heterogeneous at both its amino and carboxyl termini. Recent studies of the genetic forms of AD indicate that the aggregation and deposition of Abeta42 may be a common initiating event in all forms of AD. Here, we analyzed the amino termini of the Abeta species deposited in the AD brain, focusing specifically on species with amino-terminal pyroglutamate at position 3 (Abeta3(pE)). Immunocytochemical analysis of AD brains with an antibody specific for Abeta3(pE) confirmed that these species deposit in blood vessels and senile plaques. Using specific sandwich ELISAs, we determined the amounts of Abeta3(pE)-40 and Abeta3(pE)-42(43) in AD brain compared with other forms. This analysis showed that Abeta3(pE)-40 is closely correlated with the extent of Abeta deposition in blood vessels, whereas Abeta3(pE)-42(43) is not. In addition, Abeta3(pE)-42(43) is an important component of the Abeta deposited in senile plaques of the AD brain, constituting approximately 25% of the total Abeta42(43). In vitro comparison of Abeta1-42 and Abeta3(pE)-42 showed that Abeta3(pE)-42 is highly prone to oligomerization. These findings suggest that Abeta3(pE)-42 may be particularly important in AD pathogenesis. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11027491     DOI: 10.1006/bbrc.2000.3490

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  66 in total

1.  Massive CA1/2 neuronal loss with intraneuronal and N-terminal truncated Abeta42 accumulation in a novel Alzheimer transgenic model.

Authors:  Caty Casas; Nicolas Sergeant; Jean-Michel Itier; Véronique Blanchard; Oliver Wirths; Nicolien van der Kolk; Valérie Vingtdeux; Evita van de Steeg; Gwenaëlle Ret; Thierry Canton; Hervé Drobecq; Allan Clark; Bruno Bonici; André Delacourte; Jesús Benavides; Christoph Schmitz; Günter Tremp; Thomas A Bayer; Patrick Benoit; Laurent Pradier
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

2.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk
Journal:  Acta Neuropathol       Date:  2012-01-24       Impact factor: 17.088

Review 3.  Transgenic mouse models of Alzheimer disease: developing a better model as a tool for therapeutic interventions.

Authors:  Masashi Kitazawa; Rodrigo Medeiros; Frank M Laferla
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Detection of peri-synaptic amyloid-β pyroglutamate aggregates in early stages of Alzheimer's disease and in AβPP transgenic mice using a novel monoclonal antibody.

Authors:  Markus Mandler; Edward Rockenstein; Kiren Ubhi; Lawrence Hansen; Anthony Adame; Sarah Michael; Douglas Galasko; Radmila Santic; Frank Mattner; Eliezer Masliah
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

5.  CEREBRAL AMYLOID ANGIOPATHY AND ALZHEIMER'S DISEASE.

Authors:  Jorge Ghiso; Yasushi Tomidokoro; Tamas Revesz; Blas Frangione; Agueda Rostagno
Journal:  Hirosaki Igaku       Date:  2010-07-08

6.  PYROGLUTAMATE FORMATION AT THE N-TERMINI OF ABRI MOLECULES IN FAMILIAL BRITISH DEMENTIA IS NOT RESTRICTED TO THE CENTRAL NERVOUS SYSTEM.

Authors:  Yasushi Tomidokoro; Akira Tamaoka; Janice L Holton; Tammaryn Lashley; Blas Frangione; Tamas Revesz; Agueda Rostagno; Jorge Ghiso
Journal:  Hirosaki Igaku       Date:  2010-07-08

Review 7.  Neurotoxicity in Alzheimer's disease: is covalently crosslinked A beta responsible?

Authors:  Ryan Naylor; Andrew F Hill; Kevin J Barnham
Journal:  Eur Biophys J       Date:  2007-12-07       Impact factor: 1.733

8.  Amyloid-beta peptide Abetap3-42 affects early aggregation of full-length Abeta1-42.

Authors:  Hiromi M Sanders; Robert Lust; Jan K Teller
Journal:  Peptides       Date:  2009-02-11       Impact factor: 3.750

Review 9.  The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.

Authors:  Victor L Villemagne; Michelle T Fodero-Tavoletti; Kerryn E Pike; Roberto Cappai; Colin L Masters; Christopher C Rowe
Journal:  Mol Neurobiol       Date:  2008-08-09       Impact factor: 5.590

10.  Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases.

Authors:  Oliver Wirths; Tobias Bethge; Andrea Marcello; Anja Harmeier; Sadim Jawhar; Paul J Lucassen; Gerd Multhaup; David L Brody; Thomas Esparza; Martin Ingelsson; Hannu Kalimo; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-10-13       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.